CN104487068B - 用于利什曼病的决奈达隆、用于利什曼病的配制剂和组合 - Google Patents

用于利什曼病的决奈达隆、用于利什曼病的配制剂和组合 Download PDF

Info

Publication number
CN104487068B
CN104487068B CN201380038586.4A CN201380038586A CN104487068B CN 104487068 B CN104487068 B CN 104487068B CN 201380038586 A CN201380038586 A CN 201380038586A CN 104487068 B CN104487068 B CN 104487068B
Authority
CN
China
Prior art keywords
purposes
leishmaniasis
formulation
dronedarone
leishmania
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380038586.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104487068A (zh
Inventor
S·贝尔斯
S·尚博内
J-P·科拉维里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of CN104487068A publication Critical patent/CN104487068A/zh
Application granted granted Critical
Publication of CN104487068B publication Critical patent/CN104487068B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380038586.4A 2012-05-22 2013-05-22 用于利什曼病的决奈达隆、用于利什曼病的配制剂和组合 Active CN104487068B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261650182P 2012-05-22 2012-05-22
US61/650,182 2012-05-22
EP12306362 2012-10-31
EP12306362.0 2012-10-31
EP12306472.7 2012-11-28
EP12306472 2012-11-28
PCT/EP2013/060513 WO2013182423A1 (en) 2012-05-22 2013-05-22 Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.

Publications (2)

Publication Number Publication Date
CN104487068A CN104487068A (zh) 2015-04-01
CN104487068B true CN104487068B (zh) 2018-09-11

Family

ID=49711434

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380038586.4A Active CN104487068B (zh) 2012-05-22 2013-05-22 用于利什曼病的决奈达隆、用于利什曼病的配制剂和组合

Country Status (15)

Country Link
US (2) US20150150841A1 (enExample)
EP (1) EP2852385B1 (enExample)
CN (1) CN104487068B (enExample)
BR (1) BR112014028706B1 (enExample)
CO (1) CO7160058A2 (enExample)
CR (1) CR20140526A (enExample)
DO (1) DOP2014000257A (enExample)
EA (1) EA201492173A1 (enExample)
IL (1) IL235752A0 (enExample)
IN (1) IN2014KN02584A (enExample)
MX (1) MX368416B (enExample)
PE (1) PE20150022A1 (enExample)
PL (1) PL2852385T3 (enExample)
TN (1) TN2014000484A1 (enExample)
WO (1) WO2013182423A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200155503A1 (en) * 2017-08-03 2020-05-21 Bionoox Sa Compositions for use for treating cutaneous leishmaniasis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051383A2 (en) * 2000-12-27 2002-07-04 Genzyme Corporation Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
CN102065857A (zh) * 2008-04-18 2011-05-18 赛诺菲-安万特 决奈达隆或其可药用盐在制备用于调节血钾水平的药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002051383A2 (en) * 2000-12-27 2002-07-04 Genzyme Corporation Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
CN102065857A (zh) * 2008-04-18 2011-05-18 赛诺菲-安万特 决奈达隆或其可药用盐在制备用于调节血钾水平的药物中的用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis;SERRANO-MARTIN XENON ET AL;《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 》;20091005;第53卷(第12期);1098-6596 *
CONCURRENT CHAGAS DISEASE AND BORDERLINE DISSEMINATED CUTANEOUS LEISHMANIAS THE ROLE OF AMIODARONE AS AN ANTITRYPANOSOMATIDAE DRUG;A. E. PANIZ-MONDOLFI;《THERAPEUTICS AND CLINICAL RISK MANAGEMENT》;20080630;第4卷(第3期);659-663 *
In Vitro Anti-Trypanosoma cruzi Activity of Dronedarone a Novel Amiodarone Derivative with an Improved Safety Profile;BENAIM GUSTAVO ET AL;《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》;20120416;第56卷(第7期);3720-3725 *
The novel antiarrhythmic drug dronedarone:comparison with amiodarone;KATHOFER SVEN ET AL;《CARDIOVASCULAR DRUG REVIEWS》;20050930;第23卷(第3期);217-230 *

Also Published As

Publication number Publication date
PE20150022A1 (es) 2015-02-09
CR20140526A (es) 2014-12-01
US20160151326A1 (en) 2016-06-02
IL235752A0 (en) 2015-01-29
EP2852385B1 (en) 2019-08-21
WO2013182423A1 (en) 2013-12-12
BR112014028706B1 (pt) 2023-01-10
CN104487068A (zh) 2015-04-01
IN2014KN02584A (enExample) 2015-05-08
US20150150841A1 (en) 2015-06-04
MX2014014258A (es) 2016-04-25
MX368416B (es) 2019-10-02
CO7160058A2 (es) 2015-01-15
TN2014000484A1 (en) 2016-03-30
EP2852385A1 (en) 2015-04-01
BR112014028706A2 (pt) 2017-06-27
US9700540B2 (en) 2017-07-11
PL2852385T3 (pl) 2020-03-31
DOP2014000257A (es) 2014-12-15
EA201492173A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
Russell et al. The role of pro‐resolution lipid mediators in infectious disease
ES2988617T3 (es) Norketotifeno para el tratamiento de la hipercitocinemia y las infecciones virales
RU2633481C2 (ru) Лечение воспалительных повреждений при розацеа с помощью ивермектина
US9782426B2 (en) Anti-viral therapeutic composition
EA037085B1 (ru) Композиция для устранения заложенности носа, обладающая противовирусным действием
CN107405360B (zh) 新颖碘伏组合物及其使用方法
Wachter et al. In vitro efficacy of curcumin on Trichomonas vaginalis
EP2385835B1 (de) Verwendung von deuteriumoxid zur behandlung viraler erkrankungen des auges
KR101846048B1 (ko) 피부 및 손발톱의 치료를 위한 항진균 조성물
Ramanauskiene et al. Analysis of the antimicrobial activity of propolis and lysozyme in semisolid emulsion systems
Xiao et al. Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum
ES2702578T3 (es) Tratamiento de la inflamación dérmica crónica con norketotifeno
US20090214634A1 (en) Compositions and methods for the treatment of bladder cancer
CN104487068B (zh) 用于利什曼病的决奈达隆、用于利什曼病的配制剂和组合
CZ298269B6 (cs) Orální farmaceutický prípravek
US11351146B2 (en) Topical compositions for the treatment of cutaneous leishmaniasis
NZ606177A (en) Compositions for the treatment of actinic keratosis
Thakare et al. An update on benznidazole for the treatment of patients with Chagas disease
ES2753191T3 (es) Dronedarona para su uso en leishmaniasis, formulaciones y asociaciones para su uso en leishmaniasis
JP2019515927A (ja) 感染症の処置のための方法
CN116802174A (zh) 用于治疗神经系统病症的苏拉明的鼻内施用
OA17154A (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis
US20110070321A1 (en) Method and Composition for Cutaneous Treatment of Herpes Simplex Infections
JP7758278B2 (ja) コロナウイルス科感染症の治療又は予防
Castro-Hermida et al. Activity of an anti-inflammatory drug against cryptosporidiosis in neonatal lambs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant